SCHEMBL1301705

SCHEMBL1301705

COc1cc2cc3ccoc3cc2oc1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 8/20 0.62
HSD17B10 Q99714 6/20 0.62
CASP1 P29466 2/20 0.62
CASP7 P55210 2/20 0.62
KDM4E B2RXH2 6/20 0.54
ACHE P22303 4/20 0.54
CYP2D6 P10635 3/20 0.54
CYP2A6 P11509 3/20 0.54
MAOA P21397 3/20 0.54
CYP2C19 P33261 3/20 0.54
CYP2C9 P11712 2/20 0.54
NFKB1 P19838 1/20 0.54
HTT P42858 1/20 0.53
MCL1 Q07820 3/20 0.50
PTPN1 P18031 1/20 0.45
ALDH1A1 P00352 5/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 4/20 0.44
CYP1A2 P05177 3/20 0.44
CA12 O43570 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10336303 0.81 HTT (0.48) CYP3A4HSD17B10CASP1CASP7KDM4E
SCHEMBL4580168 0.81 MCL1 (0.55) CYP3A4HSD17B10CASP1CASP7KDM4E
SCHEMBL8897227 0.81 MAOA (0.50) CYP3A4HSD17B10CASP1CASP7KDM4E
SCHEMBL3467047 0.79 CYP3A4 (0.59) CYP3A4HSD17B10CASP1CASP7KDM4E
SCHEMBL30018039 0.78 MCL1 (0.47) CYP3A4HSD17B10CASP1CASP7KDM4E
SCHEMBL3447032 0.77 MAOA (0.47) CYP3A4HSD17B10CASP1CASP7KDM4E
SCHEMBL7754898 0.77 HTT (0.53) CYP3A4HSD17B10CASP1CASP7KDM4E
Pachyrrizine SCHEMBL12062103 0.77 CYP3A4 (1.00) CYP3A4HSD17B10CASP1CASP7KDM4E
Pachyrrizine SCHEMBL31474215 0.77 CYP3A4 (1.00) CYP3A4HSD17B10CASP1CASP7KDM4E
Pachyrrizine SCHEMBL29350520 0.77 CYP3A4 (1.00) CYP3A4HSD17B10CASP1CASP7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230050070-A1 Antimicrobial Composition ATLANTIC TECHNOLOGIECAL UNIV (IE) 2023-02-16 US claimed
WO-2017115382-A1 CUSTOMIZED TOPICAL COMPOSITION BANERJI SANJAY (IN) 2017-07-06 WO claimed
US-20160235708-A1 TOPICAL PIGMENTORY COMPOSITION BANERJI SANJAY (IN) 2016-08-18 US claimed
WO-2015049694-A9 TOPICAL PIGMENTORY COMPOSITION BANERJI SANJAY (IN) 2016-02-04 WO claimed
WO-2015049694-A1 TOPICAL PIGMENTORY COMPOSITION BANERJI SANJAY (IN) 2015-04-09 WO claimed
EP-1309333-B1 PLANT-DERIVED AND SYNTHETIC PHENOLIC COMPOUNDS AND PLANT EXTRACTS, EFFECTIVE IN THE TREATMENT AND PREVENTION OF CHLAMYDIAL INFECTIONS CONTROL OX OY (FI) 2009-09-02 EP claimed
US-20040058983-A1 Plan-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections CONTROL-OX OY (FI) 2004-03-25 US claimed
JP-2004506656-A 2004-03-04 JP claimed
EP-1309333-A2 PLANT-DERIVED AND SYNTHETIC PHENOLIC COMPOUNDS AND PLANT EXTRACTS, EFFECTIVE IN THE TREATMENT AND PREVENTION OF CHLAMYDIAL INFECTIONS Control-Ox OY (FI) 2003-05-14 EP claimed
WO-2002014464-A2 PLANT-DERIVED AND SYNTHETIC PHENOLIC COMPOUNDS AND PLANT EXTRACTS, EFFECTIVE IN THE TREATMENT AND PREVENTION OF CHLAMYDIAL INFECTIONS CONTROL-OX OY (FI) 2002-02-21 WO claimed
US-20240226170-A9 USE OF MBV FOR TREATING AUTOIMMUNE DISEASE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-07-11 US disclosed
US-20240131075-A1 USE OF MBV FOR TREATING AUTOIMMUNE DISEASE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-04-25 US disclosed
US-20230050070-A1 Antimicrobial Composition ATLANTIC TECHNOLOGIECAL UNIV (IE) 2023-02-16 US disclosed
US-20230022880-A1 Antimicrobial Composition INSTITUTE OF TECH SLIGO (IE) 2023-01-26 US disclosed
EP-4054606-A1 USE OF MBV FOR TREATING AUTOIMMUNE DISEAE University of Pittsburgh - of the Commonwealth System of Higher Education (US) 2022-09-14 EP disclosed
EP-0453497-A1 TREATMENT METHODS AND VACCINES BISACCIA, Emil (US) 1991-10-30 EP disclosed
WO-1990007952-A1 TREATMENT METHODS AND VACCINES BISACCIA EMIL (US) 1990-07-26 WO disclosed
EP-0337866-A2 5-Methoxypsoralene against depression Goupil, Jean-Jacques (FR) 1989-10-18 EP disclosed
EP-0316016-A2 Modified oligonucleotides Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1989-05-17 EP disclosed
EP-0001733-A1 5-Methoxy-psoralene as a new medicament and process for the synthesis Goupil, Jean-Jacques (FR) 1979-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058983-A1 Plan-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections PPARG, QPCT, PGC CYP3A4 1053/4885HSD17B10 1291/4885CASP1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.